Recurrence Rates for UTUC Managed with NBI-Assisted Ureteroscopy
Author Information
Author(s): Geavlete Petrisor, Iordache Valentin, Multescu Razvan, Paunescu Alexandra, Ene Cosmin, Popescu Razvan, Bulai Catalin, Geavlete Bogdan
Primary Institution: Department of Urology, “St. John” Emergency Clinical Hospital, Bucharest, Romania
Hypothesis
The study aims to evaluate the recurrence rates at three years for upper tract urothelial carcinoma (UTUC) cases managed conservatively using NBI-assisted flexible ureteroscopy and Holmium laser vaporization.
Conclusion
The recurrence rates at three years for UTUC cases managed conservatively using NBI-assisted flexible ureteroscopy and Holmium laser vaporization were lower than in patients treated without NBI assistance.
Supporting Evidence
- The relapse rate at 1 year was 3.3% in the study group compared to 8.2% in the control group.
- At 3 years, the relapse rate was 11.5% in the study group versus 18% in the control group.
- Cancer-specific survival was 93.4% in the study group versus 86.9% in the control group.
Takeaway
This study found that using special imaging technology during surgery helps lower the chances of cancer coming back in the urinary tract.
Methodology
The study involved 61 patients treated with NBI-assisted flexible ureteroscopy and Holmium laser vaporization, compared to a control group of 61 patients treated without NBI.
Potential Biases
Potential bias may arise from the single-center nature of the study and the selection of patients.
Limitations
The study has a relatively small sample size and is a single-center study.
Participant Demographics
The study included 61 patients diagnosed with superficial pyelo-calyceal urothelial tumor lesions, with 56 having low-grade tumors and 5 having high-grade tumors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website